This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Insmed (INSM), Harrow Health (HROW)

Tipranks - Tipranks - Thu Jun 11, 8:28AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM), Harrow Health (HROW) and Disc Medicine (IRON) with bullish sentiments.

Introducing TipRanks MCP for Agents

Insmed (INSM)

In a report released today, Olivia Brayer from Cantor Fitzgerald maintained a Buy rating on Insmed, with a price target of $235.00. The company’s shares closed last Tuesday at $99.04.

According to TipRanks.com, Brayer is a 1-star analyst with an average return of -3.0% and a 37.0% success rate. Brayer covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Inhibikase Therapeutics, and Pelthos Therapeutics. ;'>

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $201.00, a 109.9% upside from current levels. In a report issued on May 28, Barclays also maintained a Buy rating on the stock with a $237.00 price target.

See today’s best-performing stocks on TipRanks >>

Harrow Health (HROW)

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Harrow Health, with a price target of $60.00. The company’s shares closed last Tuesday at $33.46.

According to TipRanks.com, Flaten is a 4-star analyst with an average return of 6.5% and a 47.5% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Connect Biopharma Holdings, and Rapid Micro Biosystems. ;'>

Harrow Health has an analyst consensus of Strong Buy, with a price target consensus of $68.20, representing a 103.0% upside. In a report issued on June 3, William Blair also maintained a Buy rating on the stock.

Disc Medicine (IRON)

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Disc Medicine, with a price target of $88.00. The company’s shares closed last Tuesday at $68.34, close to its 52-week high of $68.73.

According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of 17.4% and a 49.4% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Odyssey Therapeutics, Inc., and Perspective Therapeutics. ;'>

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $103.14, a 53.8% upside from current levels. In a report issued on June 2, LifeSci Capital also maintained a Buy rating on the stock with a $100.00 price target.

Read More on INSM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).